Lilly’s Cholesterol

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

Eli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.

Business - CNBC - 15 hours ago

Lilly's weight loss drug shortage deemed over, but hurdles remain

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Stephen Lillie on the neck-and-neck race to the finish line in the US election – cartoon

World - The Guardian - October 27

Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

US group revises down upper end of full-year revenue estimates

Business - Financial Times - October 30

Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.

Business - MarketWatch - October 30

Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

We're upgrading our rating on the drugmaker to a buy-equivalent 1.

Business - CNBC - October 30

Lilly Sues U.S. to Change Hospital Drug Discount Payments

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.

Business - The Wall Street Journal - 4 days ago

Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.

Business - CNBC - October 30

Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Business - CNBC - October 31

Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

Eli Lilly blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.

Business - CNBC - October 30

Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks rise

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Business - CNBC - November 8

How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS

Robert F. Kennedy Jr. has been a vocal critic of obesity drugs belonging to the fast-growing GLP-1 class.

Business - CNBC - 4 days ago

Latest in Lilly’s Cholesterol

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

Lilly's weight loss drug shortage deemed over, but hurdles remain

Stephen Lillie on the neck-and-neck race to the finish line in the US election – cartoon

Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

Lilly Sues U.S. to Change Hospital Drug Discount Payments

Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year

Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks rise

How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS

Topics